{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"3.6","value":"2.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The time from start of study drug to time of progression or death, whichever occurs first","dispersionType":"95% Confidence Interval","groups":[{"description":"During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.\n\nCDX-3379 and cetuximab: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.","id":"OG000","title":"CDX-3379 and Cetuximab"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From first dose to the first occurrence of disease progression or death due to any cause (up to approximately 2 years)","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}